Stocks rose broadly on Tuesday as Wall Street wrapped up its best quarterly performance in decades.
The Dow Jones Industrial Average surged 217.08 points, or 0.9%, to close at 25,812.88. The S&P 500 gained 1.5% to end the day at 3,100.29 and the Nasdaq Composite advanced 1.9%. to 10,058.77. The major averages hit their session high with less than an hour left in the session.
The 30-stock Dow ended the second quarter with a 17.8% gain. That’s the average’s biggest quarterly rally since the first quarter of 1987, when it popped 21.6%. The S&P 500 had its biggest one-quarter surge since the fourth quarter of 1998, soaring nearly 20%. Meanwhile, the Nasdaq Composite jumped 30.6% for the quarter, its best quarterly performance since 1999.
“A combination of 1) Stimulus, 2) Positive trends in the virus, 3) Economic reopenings and 4) Hopes for a vaccine drove stocks higher in Q2,” wrote Tom Essaye, founder of The Sevens Report. “As we begin Q3, only one of those tailwinds is currently in place: Stimulus. That doesn’t mean we’ll see a correction, but be suspect of market rallies until we can add more forces supporting stocks, because we’re one stimulus disappointment away from an ugly day.”
hares of Facebook and Amazon rose 2.9% each to lead the gains Tuesday while Netflix advanced 1.7%. Micron also contributed to the gains, climbing more than 4% following the company’s better-than-expected earnings report. Micron also gave strong forward revenue guidance. Shares of Lululemon gained 6% on news it will acquire at-home fitness company Mirror for $500 million.
Tuesday was also the last day of the month, with the major averages posting their third consecutive monthly gain. The Dow was up 1.7% for June. The S&P 500 and Nasdaq were up 1.8% and 6%, respectively, month to date.
“It’s difficult to see the market continue the way it has been throughout the summer,” said Quincy Krosby, chief market strategist at Prudential Financial. She noted the market could become increasingly volatile if the number of coronavirus cases keeps rising and if some of the proposed virus treatments and vaccine fail. “That’s not only going to impact the biotechnology companies, but the broader market as well.”